Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

November 3, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Thanks, operator, and I appreciate everyone being here today as we go over Penumbra's results for Q3 2022. You can find the press release along with the financial tables — which contain a reconciliation from GAAP to non-GAAP — on the Investors tab of our site, www.penumbrainc.com. Over the course of this call, we'll be sharing forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Actual outcomes may differ materially from what those statements state or imply, because of various risks and uncertainties, among them those described in our 10-K for the year ended December 31, 2021, filed with the SEC. So we urge you not to place undue reliance on any of these forward-looking statements, and we suggest you look at our periodic filings with the SEC — including that 10-K I just mentioned — for a fuller discussion of these factors and other risks that could impact our future results or the market price of our stock, such as, but not limited to, how the COVID-19 pandemic affects our business, results of operations, and financial conditions. Penumbra undertakes no duty to update or revise any forward-looking statements, whether due to new information, future events, developments, or anything else. Some financial measures we discuss today are presented on a non-GAAP basis. The comparable GAAP measures, along with a reconciliation between GAAP and non-GAAP financial measures, appear in the press release we posted. Adam Elsesser, Penumbra's Chairman and CEO, and Sandra Lesenfants, our President of Interventional, will give a business update. After that, Maggie Yuen, our Chief Financial Officer, will talk about our financial results for the third quarter, and Jason Mills, our Executive Vice President of Strategy, will cover our guidance; so with that, I'll hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Appreciate that, Jee. Good afternoon, everyone, and thanks for being on Penumbra's call for the third quarter of 2022. Consolidated revenue came in at $213.7 million for Q3, which is a 12% rise versus the prior-year period — 12.4% as reported, and 15.1% on a constant currency basis. Our vascular revenue worldwide climbed to $123.4 million, a 17% gain over last year, and neuro revenue globally rose to $90.3 million, which is 6.7% higher than the comparable quarter a year back. The expansion in vascular came from our peripheral thrombectomy franchise, which was up 19.8% from a year earlier, propelled by share gains in venous, and our peripheral embolization business posted 12.4% growth versus a year ago. Within neuro, our stroke business worldwide was up 16% year-over-year, partly offset by our embolization and access businesses. Gross margins stood at 63.3%, a modest increase from a year ago and a decline from the prior quarter because of product mix. Non-GAAP operating income rose substantially, to $7.8 million, equal to 3.7% of revenue in Q3, and that figure does not yet reflect any material benefit from the reorganization of our immersive healthcare business, which we carried out in Q2; it's also worth noting that Q4 is off to a very strong start. Turning to next year, we anticipate faster growth and at least $1 billion in total revenue. We're eager to introduce three paradigm-changing products — Lightning Flash, Lightning Bolt, and Thunderbolt — which we think will fundamentally transform the way clot is removed from the body and the brain. These three launches should generate meaningful share gain for Penumbra in PE, DVT, arterial, and stroke, and speed physicians' shift to computer-orchestrated aspiration away from lytics, surgery, and medical management. On top of that, we restate our expectation that gross margins will widen in 2023 and beyond, surpassing the 70% mark within a few years. Gross margin gains won't follow a straight line, but we're confident in the effort we're putting in to deliver better gross margins across that span. Also, and maybe more significantly, we anticipate continuing to push operating profitability higher in 2023, despite prevailing macroeconomic headwinds; all told, as we reflect on this, our 29th earnings call since becoming a public company, we think the mix of our strong innovation engine plus our prospects for faster growth, widening gross margins, and rising profitability makes the coming year the most exciting in our company's history. I'd like to use most of my time on this call to discuss what's ahead next year and why we believe it matters so greatly to patients. Sandra and I have devoted a big chunk of the past three months to meeting physicians and attending medical meetings across both vascular and neuro. Unquestionably, the dominant theme running through those conversations has been a focus on advancing solutions for removing more clot faster, more easily, with less trauma to patients, and with even less blood loss. With that in mind, we're thrilled to say that what the world wants today is here. Upcoming releases of Lightning Flash, Lightning Bolt, and Thunderbolt will carry the newest improvements to our proprietary computer orchestrated technology, speeding our progress along the innovation arc in thrombectomy across both vascular and neuro. What makes these leaps achievable is our microprocessor-controlled software algorithms, which coordinate how our pump and catheters work together, allowing us to innovate at an even quicker pace. All told, our proprietary computer orchestrated innovation grants us a singular capacity to produce exponential gains in thrombectomy that mechanical devices by themselves can never achieve. Of these new products, Lightning Flash arrives first, launching in 2023, and its focus will be venous anatomy. We anticipate Lightning Flash becoming the most impactful launch in the company's history to date, extending the momentum from Lightning 12. As a matter of fact, Lightning 12 enjoyed its strongest quarter ever in the third quarter, steadily gaining share across U.S; and international venous thrombectomy, each of which rose double digits sequentially. Through the present quarter, Lightning 12 keeps capturing share in DVT and PE, and we anticipate that our growth and share gains in venous thrombectomy will speed up once Lightning Flash launches, now planned for January instead of mid-fourth quarter. Although this six-week shift in Lightning Flash's timing alters our fourth quarter projections, the beneficial effect we foresee this product having on our business in 2023 has only increased, as Jason will explain later in the call. The software and catheter technology improvements incorporated into Lightning Flash yield a revolutionary breakthrough in the way our proprietary computer-orchestrated technology makes aspiration decisions. Flash makes those decisions automatically and far more quickly. All told, the power, speed, and blood loss mitigation profile of Lightning Flash will, in my view, establish Flash as the market-defining technology for both pulmonary embolism and deep vein thrombosis once launched. Turning to the arterial side, our team keeps doing important work to develop this under-penetrated market. Even so, we still have a long way to go, since most arterial thrombosis is still treated with lytics or open surgery today. That is where the huge opportunity we see with Lightning Bolt comes in. Lightning Bolt incorporates two distinct algorithm sets. One is our proprietary modulating aspiration technology used in Thunderbolt, and the other is the technology that distinguishes clot from blood to maximize clot removal and minimize blood loss used in Lightning Flash; in Lightning Bolt, both of these algorithm sets are customized to pair with our arterial catheter system. Our excitement about Lightning Bolt's potential in arterial matches our excitement about Lightning Flash's opportunity in venous; we expect both products to have a huge impact on vascular patients as well as our business; we plan to launch Lightning Bolt during the second quarter of 2023. Now let me turn to Thunderbolt and our neuro business. At the start of this quarter, we started using Thunderbolt to treat patients in the THUNDER study. It's fair to say the product is doing just what we wanted it to do. As a result, our confidence is higher than ever today that Thunderbolt may fully transform the paradigm for ischemic stroke care, producing improved outcomes for patients; we also believe Thunderbolt may boost stroke procedural volume. Each year in the U.S., more than 200,000 people have a large vessel stroke. We believe Thunderbolt may be the technology that sparks growth in how many of those patients get treated annually. Last, our view remains that Thunderbolt will let physicians employ smaller catheters and still obtain the distinct advantages of our proprietary modulating aspiration. Quicker, more thorough clot removal. Down the road, this may enable doctors to treat still more stroke patients by moving routine care forward for both large vessel and distal occlusions; our expectation continues to be a U.S. launch of Thunderbolt in the second half of 2023. Before I hand things to Sandra to talk about our strong clinical evidence strategy, I want to note that the product development and geographic growth opportunities ahead of us extend beyond the three cornerstone products I've concentrated my remarks on up to now; we expect to launch additional new products in 2023, which likely makes next year the biggest number of new product launches in one year in our company's history. Also, in Europe, the recent launch of our RED family of stroke catheters produced sequential growth for our stroke business in the third quarter, and the launch of Lightning 12 and 7 sped up our peripheral thrombectomy growth. During 2023, we anticipate continued adoption of these products will generate accelerating growth from our European business. We're also enthusiastic about our growth opportunities in China and Japan ahead. In China, Genesis has shown itself to be a remarkable partner, and we hope to grow our business with them through additional products. In Japan, we're eager to deliver our peripheral thrombectomy products to Japanese physicians and patients in 2023 alongside our newest vascular partner, Asahi Intecc, whose management, team, culture, and reputation are highly impressive. I'll now pass the call to Sandra Lesenfants, President of our Interventional Business, for an update on our clinical work.

Sandra Lesenfants

executive
#3

Thanks, Adam, and good afternoon, everyone. For Penumbra and our teams across the U.S. and international markets, this quarter has been extremely productive and exciting. During Q3, we continued to grow the number of patients we serve around the world. With the THUNDER trial now underway, we have strong confidence that within 12 months we can deliver this unique, revolutionary system to ischemic stroke patients in the U.S. Thanks to Lightning 12 and Lightning 7, we picked up share in U.S. venous and arterial markets, and we expect the Lightning Flash and Lightning Bolt launches to speed up our growth. European vascular thrombectomy revenue increased on a sequential basis. The European launch of our RED catheters drove growth in our neuro business, and since that RED launch we are seeing bigger opportunities emerge for us among high-volume European accounts. Beyond our ongoing, high-impact innovation, investing in clinical research and scientific data will matter greatly if we are to hit both our near-term and long-term growth goals; we are entering the strongest period of clinical evidence generation in Penumbra's history. Alongside the important standard study in stroke, over the past couple of months we shared details on two randomized controlled trials set to begin in the months ahead. STORM-PE, a first of its kind RCT, will examine our computer-orchestrated aspiration combined with anticoagulation in pulmonary embolism patients against anticoagulation by itself, which remains the treatment used today for the vast majority of intermediate-high risk PE patients. The second, CHEETAH ACS, is likewise a first of its kind RCT and will enroll 1,000+ patients, focusing on acute coronary syndrome patients who have a high thrombus burden. That study will assess CAT RX aspiration as an adjunct to standard PCI versus PCI alone; we anticipate both trials will yield evidence demonstrating better outcomes for patients treated with Lightning Flash in pulmonary embolism and CAT RX in acute coronary syndrome. We believe these studies will substantially grow the number of patients in both the PE and coronary populations who could benefit from our technologies. Besides STORM-PE and CHEETAH ACS, four clinical studies are currently onboarding: STRIKE-PE, STRIDE in arterial bolt, NBBT, and MIND in intracerebral hemorrhage; in STRIKE-PE, a 60-patient cohort was presented recently, showing, among other positive data points, that both right ventricle/left ventricle ratio at 48 hours and pulmonary artery pressure dropped significantly right after the procedure while patients were on the table. Also, we recently presented 30-day data from STRIDE demonstrating a significantly lower amputation rate among arterial patients treated with our technology versus historical rates seen with traditional therapies. All told, we will keep building our body of clinical evidence to prove that computer-orchestrated innovation is impactful and transformational, since it significantly improves outcomes for stroke, PE, DVT, arterial, and acute coronary patients, the vast majority of whom still receive lytics, surgery, or medical management today. At this point, I'm going to hand the call over to Adam.

Adam Elsesser

executive
#4

Thanks, Sandra. Prior to handing things off to Maggie, I want to share some news about our immersive healthcare operation; this past quarter brought substantial strides. During the earnings call for our second quarter, I mentioned the remarkably inventive efforts being made by the United States Department of Veterans Affairs, which uses immersive computing, or VR, to assist veterans. Not long ago, we began performing work under a VA contract focused on targeted mental health therapy. This has us excited, along with further chances to deliver this technology in service of veterans and to demonstrate how it can be folded into the therapeutic workflow for patients. Also worth noting, Novant Health made an announcement in recent days that they now provide our REAL i-Series to cancer patients as they receive infusion treatments or go through diagnostic imaging. As we discussed last quarter, we'll stay disciplined with our investments, even as we carry on the vital effort to scale our platform and reach many more patients. To illustrate, starting today we are introducing our full body avatar technology, legs included. Alongside that technology, we're also rolling out a set of activities for therapists centered on the lower body. Ongoing development of our hardware and software, combined with the efforts involving the VA and other leading healthcare partners, matters a great deal. I'll pass the call to Maggie now so she can walk through our financial results for the quarter.

Maggie Yuen

executive
#5

Thank you, Adam. Good afternoon to all of you. On today's call, I'll go over our financial results for Q3 of 2022. When we talk about revenue and gross margin on this call, those figures are on a GAAP basis, whereas operating expenses and operating income are non-GAAP. You can find the corresponding GAAP measures along with a reconciliation between GAAP and non-GAAP financial measures in the press release we posted. For the third quarter, which ended September 30, 2022, total revenues came in at $213.7 million, which represents growth of 12.4% as reported and 15.1% in constant currency versus Q3 of 2021. This comes with a foreign exchange headwind of $11.6 million for the current year to date and a projected foreign exchange headwind of $18 million-$19 million for the full year. In terms of geographic mix, sales during the quarter were 69.6% U.S. and 30.4% international. U.S. growth was 10.4% as reported, while our international regions rose 17.3% as reported and 26.8% in constant currency. Turning to revenue by franchise. Our vascular business brought in $123.4 million in Q3 of 2022, up 17% as reported and 18.8% in constant currency versus the same period last year. We achieved strong double-digit growth across the U.S., EMEA, APAC, and Latin America regions. Our neuro business generated $90.3 million in Q3 of 2022, up 6.7% as reported and 10.5% in constant currency versus the same period a year ago, with growth in the neuro thrombectomy franchise driving that result. Now to gross margin. Gross margin for the third quarter was relatively flat at 63.3%, compared with 63.1% in the same quarter last year. Savings from productivity improvement continued to offset heightened inflation and supply chain pressures. Gross margin declined 120 basis points on a sequential basis, mainly due to distributor and country mix timing; generally speaking, our thrombectomy products and direct channels carry higher margins than embolization products and distributor channels. As we look ahead to 2023, we anticipate continued margin expansion, since all the new product launches will have a favorable product mix impact with volume leverage to our gross margin. Now on to our non-GAAP operating expenses, excluding amortization of acquired intangible assets of $2.4 million and $1.8 million for this quarter and last quarter, respectively. Total operating expense for the quarter was $127.5 million, or 60% of revenue, compared with $111.1 million, or 59% of revenue, for the same quarter last year. Our research and development expenses for Q3 2022 were $21.3 million, compared with $16.7 million for Q3 2021. SG&A expenses for Q3 2022 were $106.2 million, or 49.7% of revenue, compared with $94.4 million, or 49.7% of revenue, for Q3 2021 and $112.8 million compared to last quarter. While we have invested in commercial resources and infrastructure to enable us to scale and support growing demand, our SG&A expenses have reduced by $6.6 million sequentially by disciplined discretionary spend control. When it comes to our total operating costs, our approach centers on being careful about where we choose to spend. Looking ahead to Q4, we anticipate cutting another $2.5 million tied to immersive healthcare spending, and that figure will also become part of our ongoing baseline expenses. In the third quarter 2022, we posted operating income of $7.8 million, which works out to 3.7% of revenue, once you exclude amortization of acquired intangible assets — that compares with $8.8 million in operating income during the same quarter a year earlier. As the third quarter closed, our balance of cash equivalents and marketable securities stood at $184 million. Cash use during that quarter was driven by ramped-up purchases of raw materials ahead of new product launches, along with greater working capital needs. At this point, I'd like to hand things over to Jason so he can walk through our guidance.

Jason Mills

executive
#6

Thanks, Maggie, and good afternoon to all of you. Our fourth quarter is off to a really robust beginning, powered by our computer orchestrated product franchise in vascular thrombectomy along with our stroke business, since enrollment in the THUNDER trial keeps building momentum. Even with that robust beginning, we think it's wise to stay cautious regarding our 2022 guidance because of two near-term dynamics, and neither one shakes our confidence about 2023, which I'll get to shortly. To start, the Lightning Flash product launch should now happen in the first quarter of 2023, which is six weeks later than the earlier estimate of mid fourth quarter 2022. Next, an incremental $4 million-$6 million stemming from currency translations. Our revised 2022 guidance for total revenue now stands at $840 million-$845 million, versus the low end of our initial range of $860 million-$875 million that we gave on our second quarter call. The updated revenue guidance implies growth on a reported basis of 12%-13% and 15%-16% on a constant currency basis, which sits within our original expectations. Turning to 2023, we anticipate that Lightning Flash, Lightning Bolt and Thunderbolt will fuel accelerating growth and drive significant share gain in PE, venous, arterial and stroke thrombectomy, respectively. That begins in the United States, then extends around the world in 2024 and beyond. We anticipate reaching the $1 billion total revenue level in 2023. Furthermore, we anticipate considerably greater expansion to our gross margins next year thanks to favorable mix and realization of productivity gains. Lastly, we anticipate raising our operating profitability in 2023 and beyond. I'll now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#7

Thanks, Jason, Maggie, Sandra, and Jee. Everyone can see that the climate most companies are dealing with today is especially tough. I'd like to recognize the entire Penumbra team for what they've done amid these difficult conditions, and I especially want to call out three remarkable accomplishments. First, the truly world-class innovation delivered during the last 12 months. That amazing development effort hasn't simply kept going — it has sped up. Second, our operations and quality groups, along with the teams supporting them, for meeting rising demand while pushing hard to grow even more efficient, and doing so despite unrelenting supply chain obstacles throughout this year; and last, our commercial organization, for the commitment and integrity they show toward their customers and the patients they serve. There is no way I could be more proud of the individuals who make up Penumbra. Thank you. Operator, please go ahead and open the line for questions.

Executive

executive
#8

Hi, it's John on for Bill tonight. Thanks for taking our questions.

Adam Elsesser

executive
#9

Hey, John.

Executive

executive
#10

If you're saying that you're gaining share in venous, could you give us a bit more detail on whether that share is coming from other interventional competitors, or whether you're actually converting patients who have been on medical management?

Adam Elsesser

executive
#11

Right. At the time we made that remark, what we had in mind was taking share away from competing interventional devices.

Executive

executive
#12

Great. Thanks. Thoughts on any impact in China from the volume-based procurement in neurovascular?

Adam Elsesser

executive
#13

I'm sorry, say that one more time.

Executive

executive
#14

Apologies. Just some thinking regarding whether volume-based procurement rules in neurovascular are having any effect in China. A rival brought those up. They're looking to find out whether you folks are noticing anything—

Adam Elsesser

executive
#15

Yeah, sure. Jason can answer that question.

Jason Mills

executive
#16

Yes. I appreciate that question, John. It's an excellent one. As you're aware, our relationship with Genesis is quite robust, and we are truly only at the beginning of what we can do together. When it comes to the VBP policies, we at Genesis have been monitoring them carefully, and for a while now they've been part of how we consider our operations in China. Regarding our existing business there or our views on growth potential for 2023, essentially nothing has shifted.

Executive

executive
#17

Thank you.

Adam Elsesser

executive
#18

Thanks. Thank you. Hi, Larry.

Executive

executive
#19

Hi. Thanks; it's Leigh calling for Larry. Thanks for taking the question.

Adam Elsesser

executive
#20

Hello.

Executive

executive
#21

Hey there. First off, I'd like to begin by focusing on 2023. You mentioned that you still expect to reach more than a billion in revenue during the coming year. Taking the midpoint of the guidance you've provided for 2022, growth from that point would suggest 19% growth as reported, and on a constant currency basis, likely slightly above 20%. Could you expand a bit on how confident you are in reaching that figure, along with the main drivers of growth you referenced — and if possible, add some further detail? And also, should we be thinking of that as perhaps weighted more toward the second half, given when the various launches are scheduled?

Jason Mills

executive
#22

Yeah, that's an excellent question, and I'm excited to respond to it. Our level of conviction in that figure is very high — likely higher than at any point before. Keep in mind, we first provided that figure at the close of 2019, back when our size was roughly half of what it is today. And here we are, exactly where we expected to be. That's something we take real pride in. What gives us this confidence is the three foundational launches, beginning mainly with Lightning Flash. Honestly, if you haven't witnessed it, it's simple to undervalue it. But after you've seen it, overvaluing it would be difficult.

Adam Elsesser

executive
#23

This is genuinely a remarkable step forward. I'm quite thrilled about it. I believe the entire team feels the same way, and I think doctors are prepared to step into that fresh chapter. We have especially strong confidence in how things stand here regarding Lightning Flash, Lightning Bolt, and naturally, Thunderbolt, where that trial is currently in progress.

Jason Mills

executive
#24

Yes, Leigh, it's Jason here. I appreciate you asking. To expand a bit further on what you were asking regarding the timing pattern: we're definitely quite enthusiastic, and as I believe we noted during our prepared remarks, once Lightning Flash comes out, we anticipate it will be the most successful product introduction in our company's history up to this point. That one will be the first to arrive, and it should add more as the year progresses; we anticipate that its contribution will grow over the course of the year. As for Lightning Bolt, we don't expect it to arrive until the second quarter, and it will have a comparable timing pattern. Regarding Thunderbolt, we still hold the qualitative view that this product will arrive sometime in the second half. To be honest, from a quantitative standpoint, that level north of $1 billion is not really incorporated into the forecast we just provided.

Executive

executive
#25

I want to make sure I understand this correctly — Thunderbolt isn't included in that goal of more than $1 billion for the coming year, right?

Adam Elsesser

executive
#26

No. What Jason was saying is that it isn't included as a major element of that. Sure, it's certainly present, but it isn't the bulk of it, nor the main thing pushing it.

Executive

executive
#27

Understood. All right, that's useful. If I could just pose one brief follow-up regarding your Q4 guidance, it suggests roughly — let's say — growth in the low teens compared with a year earlier, yet on a sequential basis that's low single-digit expansion over Q3, and that comes in, you know, somewhat softer than your historical pattern. What's making this Q4 different? I realize you mentioned the year-over-year piece. There's the FX headwind, and you've got a delay in launching a new product, but even setting those aside and just examining the base business, typically Q4 delivers a bit more growth than what your guidance calls for.

Jason Mills

executive
#28

Sure. Leigh, I’ll start with that one, and then Adam might want to add something. I appreciate the question. Those two factors, of course, have an effect on Q4. What matters is that they have no effect on 2023. If you examine those two factors, we describe the incremental FX impact as being $4 million-$6 million on a quantitative basis, which is above and beyond what we had expected three months earlier; that is part of the sequential pattern. If you compare our earlier guidance with our current guidance, you can see the difference, which is roughly $20 million or so. The remaining portion is tied to the six-week delay in the Lightning Flash launch.

Adam Elsesser

executive
#29

It's simple arithmetic to see what our original projection was, and to understand why nobody enjoys burning time on what you'd label, quote-unquote, delays. What happened is we stumbled onto something. We figured out an approach to make it superior. With software, there are times when progress comes more easily than with hardware — catheters, that sort of thing. Things move more quickly. This approach let us take Lightning Flash to a level beyond where it previously stood. I'd put money on the fact that in hindsight, we'll describe those as the greatest 6 weeks — the finest use of resources and hours we've ever made. Sure, nobody wants to go through it, yet in my view it paid off handsomely, and it has only ramped up how thrilled we are about this product.

Executive

executive
#30

Got it. Thank you so much.

Adam Elsesser

executive
#31

Of course. Thank you.

Executive

executive
#32

Hi. This is actually Lily on for Robbie. Thanks for taking the question.

Adam Elsesser

executive
#33

Hi, Lily.

Executive

executive
#34

Hello there. On a quarter-to-quarter basis, Peripheral came in unchanged, and that outcome was somewhat weaker than our expectations. What caused this? Could it be related to personnel levels or typical seasonal patterns, or perhaps something else prevented it from expanding from one quarter to the next?

Jason Mills

executive
#35

Appreciate that question. To start, I want to make clear that our U.S. business performed well, and we kept gaining share. In our peripheral thrombectomy business in the United States, we rose more than 10% on a sequential basis. Compared with a year earlier, growth occurred in every region. On a sequential basis, distributor markets show a degree of unevenness, and that is particular to the third quarter.

Executive

executive
#36

Understood, that's useful. Perhaps more generally regarding the neuro market, clearly there have been some difficulties when it comes to competition and market growth. Could you update us on what you're observing with regard to underlying growth in neuro and how you're viewing the outlook as we head into 2023? Is some kind of market acceleration assumed within that $1 billion figure? Thanks.

Adam Elsesser

executive
#37

Absolutely, and that's a really good question. I believe your point is correct—the expansion of this market has been slower than what anybody would hope for, especially for those of us who want our technology to serve as many of these individuals as possible; that probably ties back to staffing issues, the aftermath of COVID, and other factors. Having said that, with the RED series, we keep performing very strongly when measured against competitors. For the time being, that's where our attention will remain. As we stated quite clearly during the prepared remarks, I'm of the view that given the ongoing enthusiasm surrounding Thunderbolt, after we complete the trial and all the data becomes available, we expect that could have the impact of possibly sparking renewed interest and a desire to keep expanding this market. That's what we're hoping for. We believe this is an enormous market that needs to be developed. I think the technology may assist in making that happen as we move forward; at present, our growth stems from share gains, and we take considerable pride in the RED series. They're performing very well.

Executive

executive
#38

That's helpful. Thank you.

Adam Elsesser

executive
#39

Thank you.

Maggie Yuen

executive
#40

Thank you.

David Rescott

analyst
#41

Hey, guys.

Adam Elsesser

executive
#42

Hey, David.

David Rescott

analyst
#43

Appreciate you fielding this. Hi, Jason. Hi, Adam. Thanks for answering. Nice work on the quarter. I'd like to build on a few of the remarks you made regarding the revised outlook for 2022. If someone runs a quick rough calculation, like the one you both described, and removes the added $4 million-$6 million from FX, that suggests roughly $20 million of contribution from Lightning Flash across approximately six weeks or so in the quarter. So if a person projected that forward into 2023, it would point to something above maybe $150 million or so coming specifically from that product next year. I'm just curious whether that arithmetic is correct, and what caused the six-week delay?

Adam Elsesser

executive
#44

Yes. Well, several points. To start, I believe the total came to 20. Once you subtract the four to six, the Flash amount is under 20. I want to be certain the numbers are right. It's slightly below the total, were you to extend that, just for precision. Yes, after that adjustment and calculation, that's a fair characterization. We stated quite plainly that we anticipate it being the launch with the greatest impact. It's among those offerings, let me phrase it this way. The moment a physician views this demonstration, he needs roughly 40 seconds to grasp the strength and effect this product will deliver. It's simply something; it's something. We're quite enthusiastic about it. What did you ask last? It concerned the timing of something. My apologies. I didn't catch the final portion.

David Rescott

analyst
#45

what caused this postponement.

Adam Elsesser

executive
#46

yes, I believe I covered this during a prior question, though I'll say it again. A chance came up for us to refine the algorithm somewhat. We seized that chance, since it turned an already strong product into something even stronger. As I mentioned before, those might be the finest six weeks we have ever put in. That explains why things were pushed back.

Jason Mills

executive
#47

Yes. David, I want to emphasize what Adam just said. As you’re aware, likely because you keep up with the tech sector, software and software innovation advance more quickly, so by definition, finding improvements in our computer-orchestrated portfolio can happen more quickly.

David Rescott

analyst
#48

Alright. Okay. Yeah, that's quite useful. So, my second question. I believe you may have brought up during the Q&A, perhaps five or six times, that it's fairly evident you're picking up share within the U.S., expanding in the neuro sector as well as venous. I'm curious where exactly those gains might be originating from. In other words, is it tied to new accounts? Is it usage inside those new accounts? Or perhaps just securing a larger dollar portion for each procedure? I'm simply asking why this is happening even before Flash, and did that sort of take place across the whole quarter? Was there possibly a moment during the quarter when you began noticing somewhat of a pickup in those share gains? Thanks.

Adam Elsesser

executive
#49

Let me return to our second quarter call, when we first brought up this subject and stated that we had begun to observe some share gain, especially in DVT. We highlighted that. As you're aware, there were plenty of conversations on that matter with plenty of various individuals and investors. That share kept moving our way over the course of the quarter. Physicians have attended meetings and meetings. We've been present at them, and the subjects discussed that produced that share shift have persisted and persist right up to now. We just wrapped up the VIVA meeting. The subject was brought up to us once more, not by us to others, on many, many occasions. We believe that, you know, this resulted in the robust gain in DVT.

David Rescott

analyst
#50

All right, thanks.

Shagun Singh

analyst
#51

Hi there — am I coming through clearly?

Adam Elsesser

executive
#52

Yes, hello, Shagun.

Shagun Singh

analyst
#53

Hi there. I'd like to get a clearer picture of the revised guidance. It assumes roughly $20 million, and you mentioned some fairly large figures for 2023. What's driving those assumptions? How do you arrive at those large figures? It certainly implies that your billion-dollar figure for 2023 might serve as a base case within that. Then, how should we consider the other products relatively, in terms of their revenue contribution? Thunderbolt — is it comparable, greater, or smaller? And what about Lightning Bolt — how should we think about the relative contribution from those products? Then I have a follow-up.

Adam Elsesser

executive
#54

Okay, that's quite a few questions, so let me attempt to address them, and afterward we'll take the follow-up. They are excellent questions, though. I believe we addressed what makes up that $20 million. It combines the six-week delay in launching Lightning Flash along with the extra FX, which we've put a number on. That figure is pretty solid. We also want to remind you that we stated clearly during our prepared remarks that this quarter has begun extremely well. There is nothing at all, in our view, wrong with our base business right now; as a matter of fact, it's as robust as it has ever been. That deserves repeating. I think we did say it. The delay was entirely intentional, since we wanted to improve this product further. It was already an excellent product, but we had a chance to modify or adjust the algorithm to make it even better. I believe that will turn out to be a truly brilliant choice; it's as straightforward as that; it's simply a matter of six weeks, and I'm not sure how else to phrase it. You're correct. The billion-dollar figure is what we published back in 2019. By restating it, we want to ensure we aren't providing formal guidance; that will come on our fourth quarter call. We are providing clear guidance that this is the figure we will at minimum reach. We aren't providing particular figures beyond that or in addition to that for now, though we will. In your terms, I suppose that's a solid starting base case.

Shagun Singh

analyst
#55

My apologies — let me make sure that's clear. What I'm really asking is this: take that $20 million and stretch it across 2023, and the figure you land on is $160 million. It might come out a touch under that. What I want to understand is what's behind it — what assumptions are producing those figures? And when it comes to Lightning Bolt and Thunderbolt, thinking about how much revenue each brings in, on a relative basis should we expect comparable impact, or should one land with less punch? How should we frame that? I'm sorry I didn't state it clearly the first time.

Adam Elsesser

executive
#56

No, no, that's fine. To repeat, part of that $20 million was FX, and that piece needs to be stripped out. Once you look at it and work through the arithmetic, the result is a figure below the one you just calculated — though it's still a meaningful one.

Shagun Singh

analyst
#57

Correct.

Adam Elsesser

executive
#58

After that, you factor in what Lightning Bolt adds on top, and that shows up sooner, plus Thunderbolt, which, as we've stated, represents just a fairly modest share of the total; that's the way the calculation comes together. Once more, we aren't providing exact figures for any of those individual products at this point. Doing so wouldn't be logical. In terms of direction, I believe you've got the picture.

Shagun Singh

analyst
#59

Understood. As a quick follow-up, I was hoping to get a feel for your thinking on OpEx for next year. From what I gather, you've signaled that you anticipate increasing it more slowly — at a rate beneath that of sales growth. Could you walk us through that a bit more clearly? Is it 50% of the sales growth rate? Is it under that but still at double-digit levels? And then, whatever you're able to tell us about reaching, say, that initial 20% operating margin target, that would be wonderful. Thanks for fielding the questions.

Maggie Yuen

executive
#60

Yes, great. Appreciate the question. As Adam said, we aren't providing formal guidance regarding our future operating margin, but our aim is to keep enhancing both our gross margin and the bottom-line operating margin. I'm truly thrilled that we've reached a stage where we're positioning our business for faster growth along with ongoing margin expansion.

Shagun Singh

analyst
#61

Thank you.

Adam Elsesser

executive
#62

Thank you.

Pito Chickering

analyst
#63

Hi, everyone. I appreciate you letting me ask. A major factor—

Adam Elsesser

executive
#64

Thanks.

Pito Chickering

analyst
#65

Looking ahead to the coming year, what can you share about these launches? Do you have any details on the way these new items will be priced for you? For instance, if we use the rough figure of $150 million from Lightning Flash, what portion of that comes from volumes as opposed to pricing?

Adam Elsesser

executive
#66

Yeah, that is a wonderful question. Pricing has not been established or made public by us. There could, you know, be some part of that, but the great majority is a rise in usage and procedures. Like I mentioned, when you observe this product functioning, it's difficult not to recognize the value that this product will deliver to patients.

Pito Chickering

analyst
#67

Alright, circling back to the margin topic. So, assuming revenues climb by $160 million in the coming year — I get that you're not providing official guidance — do you intend to keep reducing what you put into immersive healthcare even with that revenue increase, or will you ramp those investments up as revenues grow?

Adam Elsesser

executive
#68

Yeah, excellent question. We definitely aren't. At this point there's no intention to reduce those investments further. Last quarter, as we mentioned, we restructured that department so it would spend somewhat less and operate with greater discipline. That's turning out to be a highly effective choice, and we're benefiting a great deal from it. As you heard, during this call we unveiled the full body avatar, which includes legs. When you consider final VR, that's an enormous subject. In healthcare it's significant because certain areas of the body, including the leg, require rehabilitation, and it lets you undergo a more complete immersion and consequently recover better, yet outside of healthcare, that's something numerous other firms, especially certain large ones, still haven't managed to accomplish. We take real pride in that. Once more, the collaboration with the VA is at an early stage so far, but it has truly been remarkable. We will keep carrying out that work. I believe it's meaningful work, and I believe it will assist many people. I don't anticipate needing to increase spending beyond roughly where we stand now until revenue essentially contributes enough to justify it.

Pito Chickering

analyst
#69

Would you be willing to share some sort of range for what those expenses currently look like as they move through the P&L? Thanks.

Adam Elsesser

executive
#70

Pito, is your question directed at us regarding Immersive Healthcare specifically, or are you asking about OpEx in general?

Pito Chickering

analyst
#71

Regarding Immersive Healthcare specifically — at this stage, what does the cost structure look like within the P&L right now for that business?

Adam Elsesser

executive
#72

Yeah. We aren't ready to break those specifics down; in Maggie's portion we did put numbers to the overall quarterly savings you'll begin to observe starting next quarter. Past that, that's about as far as those figures go in terms of what we'll disclose at this time.

Pito Chickering

analyst
#73

Great. Thanks so much.

Adam Elsesser

executive
#74

All right. Thank you.

Jason Mills

executive
#75

Thank you, Pito.

Mike Matson

analyst
#76

Yes. I appreciate you answering my questions. So, to start, given that every one of these smart aspiration platforms you plan to introduce is electronic, do you believe you currently hold enough semiconductor parts to satisfy all the demand, or at least have the visibility needed to obtain them in the coming year to satisfy that demand?

Adam Elsesser

executive
#77

Yes. That is genuinely an excellent question, and it's one I began directing to our operations group a while back, while we were preparing for this and verifying that we'd be fine. As Maggie mentioned in her part, we were somewhat ahead of the curve by purchasing materials in advance of these launches. With any supply chain matter, I'm reluctant to speak in absolute terms, since it has proven to be an enormous difficulty for every business and we aren't exempt from that; still, what I can say right now is that thus far, things look good. We've been putting in tremendous effort to stay ahead of it, and I'd say our position is fairly solid at this moment.

Mike Matson

analyst
#78

All right. Regarding the THUNDER trial, will its findings be released publicly at some stage prior to either an FDA submission or before the product actually gets cleared and launched? For instance, would we be able to see that? And might that serve as a sort of positive catalyst if the data turns out well?

Adam Elsesser

executive
#79

Yes; that really hinges on the timing, you know, which meeting happens to come along, that's going to be the biggest question. You know, if a neuro meeting falls at a point that allows us to do that ahead of clearance, we would definitely want to do so. I simply can't fully forecast the timing down to which meeting we'll be able to do that at, but that would definitely be a reasonable expectation.

Mike Matson

analyst
#80

All right, regarding those RED catheters over in Europe — I believe they only came out quite late during Q3. How much did that actually contribute? It seemed as though your neuro segment performed somewhat better, yet did it move the needle materially, or will that show up more during Q4?

Adam Elsesser

executive
#81

Yes. Over in Europe, the RED catheters are performing nicely, and we did highlight that. It has been quite enjoyable. Everyone had been anticipating them for a long while. When they at last arrived, folks felt thrilled. They function effectively. Regarding the neuro segment, you know, within the U.S. it has kept performing very strongly as well. We highlighted that. On the share gain front, those catheters are performing nicely. There is considerable enthusiasm regarding us as an organization and our offerings once more in stroke. We feel extremely, extremely optimistic, and I believe that stems largely from the catheters, partly from the buzz surrounding Thunderbolt as folks discuss it. I think the mix has positioned us for genuine success moving ahead.

Mike Matson

analyst
#82

All right, understood. Thanks.

Adam Elsesser

executive
#83

Thanks. Appreciate it, Mike.

Adam Elsesser

executive
#84

Hi, Mike. Good afternoon.

Michael Sarcone

analyst
#85

Hi there. Good afternoon, and thank you for allowing me to ask. My initial question concerns Thunderbolt. I was curious to learn your perspective on how quickly the product will be taken up after you get the green light; regarding the customers you already have, could you share what you anticipate for the adoption timeline? Will this be a fairly fast and frictionless switch, or are there limiting elements we ought to consider?

Adam Elsesser

executive
#86

That's an excellent question. Once more, this is one that, as you're aware, sits kind of in the latter half of 2023, rather than the earlier half like Lightning Flash and Lightning Bolt, which, as we've mentioned, should be more meaningful in the year ahead. When it comes to Thunderbolt, both returning and, you know, brand-new buyers, I'd say, are comparable. The single cohort that moves quickest will be those participating in the trial. As you know, they've already had hands-on experience with it, and they don't even require an in-service session since they've been performing procedures. That cohort will move most rapidly. Regardless of whether you presently employ a RED catheter with continuous aspiration, or you prefer to use catheters from other companies or some mix of devices, the in-service training on operating Thunderbolt will remain identical. There won't be any basic distinction among those folks who are, in a sense, taking this up; we've actually witnessed this during the trial, where individuals who enrolled and began—people who, as you know, hadn't previously been particularly heavy users of our offerings. Once again, the in-service is unchanged, and the ramp-up happens quite fast for both sets of individuals.

Michael Sarcone

analyst
#87

Understood. Alright, that's useful. For my next question, would you be able to discuss peripheral vascular patterns across Europe? I'm especially curious about the way the Lightning Seven and Twelve items are advancing.

Adam Elsesser

executive
#88

Once more, we highlighted that point. Lightning keeps performing quite strongly across Europe. As before, each nation differs somewhat when it comes to the reimbursement approach, yet those individuals who have adopted it remain committed to it. It is, once again, either Lightning 12 or Lightning 7, based on where you are. We mentioned that. The momentum has been quite encouraging. Once more, those figures are fairly modest set against the remainder of our Lightning 12 and 7 operation, though definitely favorable.

Michael Sarcone

analyst
#89

Got it. Thank you.

Adam Elsesser

executive
#90

Yeah, thank you.

Adam Elsesser

executive
#91

Hey there, Margaret.

Margaret Kaczor

analyst
#92

Good afternoon, everybody. Appreciate you fielding my questions. I'm sorry — I'm sort of jumping between calls, so if this already came up, hopefully I won't eat up too much of your time. But maybe to start, you folks have a bunch of launches coming, right, as we think about the coming 12 to 18 months. I think how we and others see it is that there should be, hopefully, a pleasant acceleration in unit growth, plus share gains and pricing. I was just wondering — looking at that $1 billion goal for 2023, could you share any color or flavor on the separate components, particularly around market share, whether it's in vascular or stroke, RED Lightning pricing, anything along those lines? Thanks.

Adam Elsesser

executive
#93

Yes. Yeah, no, that's a good question. The largest chunk will clearly be Lightning Flash. We discussed that in PE and DVT. Number two, and that's partly simply because it gets the full year, Lightning Bolt should have roughly three quarters of that. That would be the next largest. Stroke, meaning Thunderbolt, will land in the second half. Naturally, that makes it the smallest contributor. We did address a question or comment that this figure is, on a quantitative basis, a fairly modest portion of our growth for next year.

Margaret Kaczor

analyst
#94

All right. That covers the volume piece. Could you tell us anything regarding what you're assuming about market share, or how market growth dynamics might play out in those segments?

Adam Elsesser

executive
#95

Yes. The bulk of that expansion is going to be driven by share gains, market growth, or some mix of both. If the suggestion is that pricing accounts for the majority of it, that isn't right. As for most of it — again, we haven't made any price announcement or anything like that. Price could contribute a small portion, but share and market growth are where the majority is coming from.

Margaret Kaczor

analyst
#96

All right. As a quick follow-up, with all the staffing challenges out there, are you observing any shift when it comes to enrollment in any of your clinical trials, or would you say things are moving along the way they normally do for you folks? Thanks.

Adam Elsesser

executive
#97

Yes; that's a great question; providing a definitive answer on a comparative basis is tough. We haven't conducted a neuro trial like this in quite some time, so it's difficult to say. Enrollment is still ongoing, so on a comparative basis, I'd call it pretty, you know, normal. You know, without a doubt, you know, people are constantly voicing complaints about their staffing problems and they have less support than they once did. Up to this point, that doesn't appear to be affecting either our core business or our clinical trials.

Margaret Kaczor

analyst
#98

Okay. Great. Thanks, guys.

Adam Elsesser

executive
#99

Yeah, thank you.

Maggie Yuen

executive
#100

Appreciate that, Margaret.

Jee Hamlyn-Harris

executive
#101

Thanks to you as well, operator. Speaking for the whole team here at Penumbra, we appreciate your time listening in. We're eager to bring you our latest when the call for the fourth quarter comes around.

Operator

operator
#102

This concludes today's conference call. Thank you for your participation. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.